Effectiveness and Safety of the Administration of Intravenous Prostaglandin E1 Analog in the Reduction of Mortality and Complications of Patients With COVID-19
Overview
- Phase
- Phase 2
- Intervention
- Standard therapeutic protocol
- Conditions
- Covid19
- Sponsor
- Alonso Vera Torres
- Primary Endpoint
- Mortality
- Status
- Withdrawn
- Last Updated
- 2 years ago
Overview
Brief Summary
The Clinical trial aim to evaluate the effectiveness and safety of the administration of the intravenous prostaglandin E1 analog in the reduction of mortality and complications of patients with COVID-19 diagnosis. Therefore the investigators propose an open randomized clinical trial in the Fundación Santa Fe de Bogota
Detailed Description
COVID-19 is a public health problem that has spread throughout the world and has forced different scientific societies to consider effective measures to control the increasing spread of the disease. This disease is presumed to follow a virologic pattern similar to SARS-CoV-1 (Severe acute respiratory syndrome coronavirus 1) . The disease spectrum includes asymptomatic stage and pre-symptomatic , mild infection uncomplicated, mild and severe pneumonia and the acute Respiratory distress syndrome (ARDS) constituting the point of no return characterized by ventilatory mechanics preserved with severe refractory hypoxemia. The pulmonary involvement of patients with COVID-19 causes an endothelial injury, which can be associated with changes in vascular permeability, manifesting as thrombotic, venous and arterial disease in patients with COVID-19. Alprostadil, a prostaglandin E1 analog that has a vasodilator mechanism, inhibitory property of platelet aggregation and inducer of bronchodilation, promises to prevent complications of SARS-CoV2. In addition to that Alprostadil has been used in other clinical trials as treatment for the acute respiratory distress syndrome caused by Influenza, in which it showed no harm or benefit, nonetheless the pathophysiology of the acute distress respiratory syndrome caused by Influenza and COVID-19 are similar in macroscopic changes but very different in microscopic changes which is why it is important to evaluate the effectiveness and safety of the administration of intravenous prostaglandin E1 analog in the reduction of mortality and complications of patients with COVID-19 diagnosis. Therefore the investigators propose an open randomized clinical trial, where patients in the intensive care unit of the Fundación Santa Fe de Bogotá are randomized into two groups, where one is going to be treated with standardized treatment after the guidelines recommendations of the Colombian Infectology Society and the other one is going to receive the same standardized treatment and Alprostadil infusion for a maximum of 7 days. During the infusion of the Alprostadil the patient will be carefully monitored by the intensive care unit team. After the Infusion the patient will be followed up for 30 days in which the mortality and hypoxemia resolution will be monitored. Key words: COVID-19, Prostaglandin E1 Analogue, Alprostadil, Mortality, Acute respiratory distress syndrome
Investigators
Alonso Vera Torres
Trasplantation surgery
Fundación Santa Fe de Bogota
Eligibility Criteria
Inclusion Criteria
- •Patient older than 18 years of age
- •COVID19 diagnosis:
- •RT PCR for COVID-19 positive in respiratory tract sample (nasopharyngeal swab, sputum, bronchoalveolar lavage)
- •At least 2 of the following symptoms: cough, odynophagia, dyspnea, asthenia, adynamia, gastrointestinal symptoms.
- •Findings compatible with viral pneumonia on chest tomography or chest radiography.
- •Risk of respiratory deterioration given by at least 1 of the following:
- •Hypoxemia: PaO2 \<60 mmHg, SaO2 \<90% or supplemental O2 requirement to maintain SaO2\> 90%
- •Call Score ≥ 9 points
- •FR\> 30 / min
- •PaO2 / FiO2 less than 200
Exclusion Criteria
- •Allergy or sensitivity to PEG1 analog or components
- •Arterial hypotension defined as blood pressure less than 90/60 mm of mercury or mean arterial pressure less than 65mm of mercury or BP requirement \<80/50 mmHg or TAM 60 mmHg with norepinephrine requirement greater than 0.1 mcg / kg / min
- •Severe hypertension defined as systolic blood pressure greater than or equal to 180 mm of mercury and / or diastolic blood pressure greater than or equal to 110 mm of mercury
- •Bradycardia defined as heart rate less than 60 beats per minute
- •Previous events of priapism or penile anatomical changes
- •Sickle cell disease, multiple myeloma, leukemia, polycythemia vera, thrombocythemia predisposing to priapism
- •Hemorrhagic diathesis
- •Active peptic ulcer, trauma, or recent brain hemorrhage.
- •Abnormal pulmonary venous return with obstruction
- •Pregnancy: A pregnancy test will be performed upon admission of the patient to the study (if applicable).
Arms & Interventions
Standard therapeutic protocol
1. Dexamethasone (4mg ampoule, intravenous) 2. Tocilizumab (8 mg / kg (maximum dose 800 mg) IV, maximum 3) 3. Empirical Antibiotic Therapy in patients with suspected pneumonia (according to management guidelines) 4. Enoxaparin (40mg prefilled syringe) 5. Enoxaparin (20mg, 40mg, 60mg, 80mg prefilled syringe) 6. Low molecular weight heparin (5000IU prefilled syringe)
Intervention: Standard therapeutic protocol
Standard Therapeutic Protocol + PGE1 Analog
Analog of PGE1 + Standard therapeutic protocol Standard medical treatment: 1. Dexamethasone (4mg ampoule, intravenous) 2. Tocilizumab (8 mg / kg (maximum dose 800 mg) IV, maximum 3) 3. Empirical Antibiotic Therapy in patients with suspected pneumonia (according to management guidelines) 4. Enoxaparin (40mg prefilled syringe) 5. Enoxaparin (20mg, 40mg, 60mg, 80mg prefilled syringe) 6. Low molecular weight heparin (5000IU prefilled syringe)
Intervention: Analogs, Prostaglandin E1
Standard Therapeutic Protocol + PGE1 Analog
Analog of PGE1 + Standard therapeutic protocol Standard medical treatment: 1. Dexamethasone (4mg ampoule, intravenous) 2. Tocilizumab (8 mg / kg (maximum dose 800 mg) IV, maximum 3) 3. Empirical Antibiotic Therapy in patients with suspected pneumonia (according to management guidelines) 4. Enoxaparin (40mg prefilled syringe) 5. Enoxaparin (20mg, 40mg, 60mg, 80mg prefilled syringe) 6. Low molecular weight heparin (5000IU prefilled syringe)
Intervention: Standard therapeutic protocol
Outcomes
Primary Outcomes
Mortality
Time Frame: 6 month
Death during or at the end of the intervention
Secondary Outcomes
- ICU stay(6 month)
- Hypoxemia Resolution(6 month)
- Days with high flow oxygen(6 month)
- Days of invasive mechanical ventilation prior to administration of PGE1 ANALOG(6 month)
- Evolution time of the disease(6 month)
- Days from admission to intensive care unit and administration of ANALOG PGE1(6 month)